Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10216447 | 1.00 | OPRM1 (0.36) | OPRM1OPRL1DPP4KCNA3OPRK1 | |
| SCHEMBL10217085 | 0.89 | ACHE (0.36) | OPRM1OPRL1KCNA3OPRK1OPRD1 | |
| SCHEMBL14708016 | 0.86 | OPRL1 (0.40) | OPRM1OPRL1DPP4OPRK1OPRD1 | |
| SCHEMBL10216732 | 0.86 | OPRL1 (0.40) | OPRM1OPRL1DPP4OPRK1OPRD1 | |
| SCHEMBL10216738 | 0.86 | OPRL1 (0.40) | OPRM1OPRL1DPP4OPRK1OPRD1 | |
| SCHEMBL10216430 | 0.85 | PIK3CD (0.31) | — | |
| SCHEMBL10216451 | 0.85 | PIK3CD (0.31) | — | |
| SCHEMBL10216497 | 0.81 | ACHE (0.32) | DPP4JAK2JAK1TYK2JAK3 | |
| SCHEMBL10216485 | 0.81 | ACHE (0.32) | DPP4JAK2JAK1TYK2JAK3 | |
| SCHEMBL10216434 | 0.81 | ACHE (0.32) | DPP4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | OPRM1 2440/4885OPRL1 3570/4885DPP4 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.